Jiangsu Yahong Meditech Co., Ltd. (688176.SH) announced that the results of its Phase Ib clinical trial for APL-1401, targeting moderate-to-severe active ulcerative colitis, were selected for presentation at the 19th European Colorectal Congress (ECC). The data was shared in a poster format. APL-1401 is an orally administered innovative drug developed in-house with a novel mechanism for treating autoimmune diseases. It functions as a potent and selective dopamine beta-hydroxylase (DBH) inhibitor. By blocking DBH, APL-1401 disrupts the sole catalytic enzyme converting dopamine (DA) to norepinephrine (NE), leading to increased DA and decreased NE levels, thereby restoring intestinal immune homeostasis.